A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
This clinical trial is looking at new treatments for Diffuse Large B-cell Lymphoma (DLBCL), a type of blood cancer. Researchers are comparing two treatment combinations for people who have just been diagnosed. One is a standard treatment, and the other adds a new drug called Polivy. The main goal is to find out if the new combination can help people live longer without their cancer getting worse, and whether it's safe. They will also look at side effects, how patients feel, and if the cancer shrinks. This is a Phase III study, meaning it’s a big, final step to see if the new medicine should be approved for wider use.
At a glance
What is this study about?
Imagine you've just been diagnosed with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). Doctors want to find the best way to treat it. This study is like a careful comparison between two different treatment plans to see which one works better and is safer for people who are newly diagnosed.
One treatment plan is already well-known and often used. The other plan uses this standard treatment but adds a new medicine called Polivy. By comparing these two carefully, researchers hope to discover if adding Polivy can improve how long people stay well without their cancer returning or getting worse. They also want to understand if it causes any different or more severe side effects.
The main thing the doctors are watching for is how long patients live without their cancer getting worse or coming back. This is called 'progression-free survival'. They will also look at other important things, like how many people's cancer shrinks completely, their overall health and well-being, and any side effects they might experience. This kind of study, called a 'Phase III' trial, is a crucial step before a new treatment can become widely available.
Key takeaways
- This study compares a new treatment with a standard one for newly diagnosed DLBCL.
- It aims to see if adding Polivy to the standard treatment improves outcomes and is safe.
- Patients are randomly assigned to one of two treatment groups, and neither they nor their doctor will know which one.
- The main goal is to measure how long patients live without their cancer getting worse.
- It's a large, final-stage study to determine if the new treatment should be approved.
- Your well-being and side effects will be carefully monitored throughout the study.
Who may be eligible?
This study is for adults aged 18 and over, of any gender. You would be considered if you have recently been diagnosed with Diffuse Large B-cell Lymphoma (DLBCL) and haven’t started treatment for it yet.
There will be other detailed medical criteria that the doctors will check to make sure the study is a safe and suitable option for you. This might include certain health conditions you have, or medicines you are already taking.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you recently been diagnosed with Diffuse Large B-cell Lymphoma (DLBCL)?
- Have you NOT started any treatment for your DLBCL yet?
- Are you able to travel to a clinic or hospital for regular appointments and treatments?
What does participation involve?
If you take part in this study, you will be randomly assigned to receive one of two treatment combinations: either the standard treatment or the standard treatment plus the new drug, Polivy. It's like flipping a coin, so neither you nor your doctor will choose which one you get, and you won't know which one it is (this is called 'double-blind').
You'll have regular hospital visits for your treatments and check-ups. Doctors will monitor you closely, using scans and tests to see how the treatment is working and to look for any side effects. You'll also be asked to complete questionnaires about how you're feeling and your quality of life. The total time you're involved in the study will include the treatment period and a follow-up period to continue monitoring your health, which could last several years.
Potential risks and benefits
Locations (8)
- —UnverifiedBelgium
- —UnverifiedPoland
- —UnverifiedFrance
- —UnverifiedGermany
- —UnverifiedSpain
- —UnverifiedAustria
- —UnverifiedCzechia
- —UnverifiedItaly
Common questions
What is Diffuse Large B-cell Lymphoma (DLBCL)?
It's a type of fast-growing cancer that affects white blood cells called lymphocytes, which are part of your immune system.
What is a 'Phase III' study?
It's a large study comparing a new treatment to the standard one. It helps confirm if the new treatment is better and safe enough to be widely available.
Will I know which treatment I'm getting?
No, this is a 'double-blind' study, meaning neither you nor your doctor will know if you're receiving the standard treatment or the one with the added new drug. This helps keep the results fair.
What does 'progression-free survival' mean?
It means the length of time you live after treatment without your cancer growing or coming back.
Can I stop participating in the trial if I want to?
Yes, you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.